This evidence provides the basis for the clinical assessment in cancer treatment of the repurposed drug maraviroc, as a single agent or in combination with immune checkpoint inhibitors or DNA damaging agents to potentiate their cytotoxic activity, and of drugs capable to decrease CCL5 levels in tumor tissues. The gene discussed is CCL5; the disease is cancer.